Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tredaptive

- PMLiVE

EMA reaffirms guidance on paracetamol use during pregnancy

The guidance follows recent US comments about a possible link to autism

- PMLiVE

Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

- PMLiVE

David Weinreich appointed as Merck’s Global Head of R&D and CMO, Healthcare

Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site

- PMLiVE

EMA orphan drug designation given to ReAlta for graft-versus-host disease therapy

This follows preliminary results from the company's ongoing phase 2 trial

- PMLiVE

Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

The reference medicine holds approvals for multiple HER2-positive breast cancer indications

Biogen Idec building

Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA

The neuromuscular disease affects approximately one in every 10,000 babies worldwide

- PMLiVE

Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation

The updated vaccine was shown to generate an improved response against currently circulating variants

- PMLiVE

MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease

Approximately one in every 70,000 people are affected by the tumour-causing genetic disease

- PMLiVE

Merck and Daiichi Sankyo to jointly develop T-cell engager in deal worth over $170m

The partners will evaluate MK-6070 as part of a combination treatment for small cell lung cancer

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion

More than 165,000 new cases of bladder cancer are diagnosed in the EU every year

- PMLiVE

Merck’s Keytruda combination recommended by NICE for advanced gastric cancer

More than 6,500 new cases of gastric cancer are diagnosed in the UK every year

- PMLiVE

Merck’s investigational RSV monoclonal antibody clesrovimab shown to protect infants

The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links